Earlier today Bavarian Nordic announced it had signed a contract with the US government, the aim of which it is to examine if the company’s vaccine technology can be used against other diseases. According to CEO Anders Hedegaard the deal is a direct consequence of a year-long collaboration with the Americans concerning the company’s technology.
“This is an extension of the many discussions we have had concerning a number of other areas of collaboration. Aside from being used for the smallpox vaccine, our technology also has the potential to be utilized in other areas. The Americans have had an interest in - and a dialogue with us about - how a development program could be initiated and now we have done just that.”